04.10.2023 • News

AmbioPharm Appoints Brian Gregg as CEO

Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.

Gregg joins AmbioPharm after a 32-year career at Bachem Americas, where he most recently held the position of chief operating officer. He holds an MBA from the San Diego State University, US, and a Bachelor of Arts degree in Chemistry from the US University of California at San Diego.

Juncai (Chris) Bai, Chairman of the Company, said: “We are excited to welcome Brian to our executive team. He has both the leadership experience and necessary background to be immediately effective in growing our business in the U.S. and globally, and we look forward to working with him as we continue to expand on our service offerings and global customer base.”

Source: AmbioPharm
Source: AmbioPharm

Company

Logo:

AmbioPharm, Inc.

1024 Dittman Court
SC 29842 North Augusta
US

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.